Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
1.42(c) 1.46(c) 1.56(c) 1.563(c) 1.54(c) Last
5 523 294 1 005 250 1 115 811 380 981 427 215 Volume
+5.97% +2.82% +6.85% +0.19% -1.47% Change
More quotes
Financials ($)
Sales 2018 -
EBIT 2018 -33,0 M
Net income 2018 -34,4 M
Debt 2018 -
Yield 2018 -
Sales 2019 6,52 M
EBIT 2019 -33,0 M
Net income 2019 -36,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 23,0x
Capitalization 150 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development.It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.The company focuses on cell therapies for... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on PLURISTEM THERAPEUTICS INC
09/18 PLURISTEM THERAPEUTICS INC. (NASDAQ : PSTI) Files An 8-K Other Events
09/18 PLURISTEM THERAPEUTICS INC : Other Events (form 8-K)
09/18 PLURISTEM THERAPEUTICS INC. : Biotech Stocks Surging in September
09/18 PLURISTEM THERAPEUTICS : U.S. FDA Grants Fast Track Designation to Pluristem&rsq..
09/18 U.S. FDA Grants Fast Track Designation to Pluristem's PLX-PAD for the Treatme..
09/13 Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong K..
09/11 Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial High..
09/07 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
09/06 PLURISTEM THERAPEUTICS : Stem cell co Pluristem awarded $8.7m EU grant
09/05 $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU H..
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/24$PSTI - Pluristem Therapeutics, Inc. #PSTI Stock Rating Lowered by Zacks Inve.. 
09/24Pluristem Therapeutics, Inc. $PSTI Stock Rating Lowered by Zacks Investment R.. 
09/22Pluristem Therapeutics downgraded by Zacks Investment Research to sell.  
09/21HC Wainwright Reiterates “Buy” Rating for Pluristem Therapeutics, Inc. $PSTI .. 
09/19Pluristem Therapeutics, Inc. $PSTI Receives Buy Rating from HC Wainwright  
More tweets
Qtime:18
News from SeekingAlpha
09/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 19, 2017
09/18 PREMARKET GAINERS AS OF 9 : 05 am
09/18 Pluristem's PLX-PAD Fast Track'd for critical limb ischemia; shares ahead 20%..
09/14 PLURISTEM THERAPEUTIC INC. : A Biotech Company Inspired By Life
09/13 Pluristem awarded two patents in Hong Kong covering cell therapy for CLI and ..
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Technical analysis trends PLURISTEM THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 2,75 $
Spread / Average Target 79%
EPS Revisions
Managers
NameTitle
Zami Aberman Chairman & Co-Chief Executive Officer
Yaky Yanay President, Co-Chief Executive Officer & Director
Sagi Moran Vice President-Operations
Erez Egozi Chief Financial Officer, Secretary & Treasurer
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS INC.9.30%150
INCYTE CORPORATION14.74%23 351
QUINTILES IMS HOLDINGS INC23.89%20 370
LONZA GROUP56.52%19 634
CELLTRION, INC.--.--%15 568
ALNYLAM PHARMACEUTICALS, INC.201.60%10 439